Rhythm Pharmaceuticals (RYTM) announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek 2025, held last week in Atlanta, GA. Dr. Roth delivered an oral presentation detailing previously disclosed results from a post-hoc analysis of Phase 3 TRANSCEND data of setmelanotide in patients with acquired hypothalamic obesity who received concomitant GLP-1 therapy during the trial. Highlights from the presentation include: -27.1% mean placebo-adjusted difference in BMI reduction in patients treated with setmelanotide and GLP-1 therapy concurrently compared with GLP-1 therapy and placebo; and -19.0% mean placebo-adjusted difference in BMI reduction in patients treated with setmelanotide compared with placebo; none of these patients were on GLP-1 therapy during the trial.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $114 from $105 at Canaccord
- Positive Outlook for Rhythm Pharmaceuticals Despite FDA Review Delay and Financial Shortfall
- Rhythm Pharmaceuticals Faces FDA Review Extension
- Rhythm announces FDA extension of review period for IMCIVREE
- Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Optimism